Exclusive Summary

• Manufactured under US-FDA GMP protocols with ANDA currently under active review, leveraging world-class quality endorsements to guarantee accelerated geographic registrations via the 'Reliance Pathway' and ensure regulatory dominance in emerging markets like LATAM, MENA, and ASEAN.
• Offers a unique and comprehensive full-spectrum dosing matrix (12.5mg, 25mg, 50mg, and 75mg), perfectly targeting the strict clinical demands for precise dose titration in pediatric ITP and low-body-weight demographics to solidify ultimate strategic differentiation.
• Strategically timed for FDA approval in 2026, catching the exact global patent-cliff wave (salt/formulation patents expiration) to aggressively seize generic conversion dividends of the booming $2.2+ billion blockbuster Promacta/Revolade.
• Empowered by China's advanced API-and-Formulation integrated manufacturing ecosystem, it provides disruptive cost leadership in the high-barrier oral targeted therapy segment, securing massive profit margins and supreme winning hit-rates in national pharmaceutical tenders for B2B distributors.